ARTICLE | Clinical News
MCItect: Clinical trial data
November 4, 2013 8:00 AM UTC
Data from 157 patients in a U.S. and European calibration study showed that MCItect had 75% total prediction accuracy for detecting patients converting to AD within 2 years, with 75% sensitivity and 73% specificity. MCItect achieved 88% total accuracy amongst patients with >=1 apolipoprotein E (APOE) allele (n=25). DiaGenic said a validation study with MCItect will require a strategic partnership or additional funding. ...